From: The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes
 | Small molecule metabolic process (GO:0044281) | Cholesterol metabolic process (GO:0008203) | Sterol metabolic process (GO:0016125) | Cholesterol biosynthetic process (GO:0006695) | Sterol biosynthetic process (GO:0016126) |
---|---|---|---|---|---|
iPSC cardiomycytes treated with trastuzumab | |||||
 Genes uploaded to enrichment analysis | 428/517 | 428/517 | 428/517 | 428/517 | 428/517 |
 Uploaded genes in category | 98 | 12 | NS | 8 | 8 |
 Expected genes in category | 45.92 | 2.24 | 0.78 | 0.88 | |
 Category fold enrichment | 2.13 | >5 | >5 | >5 | |
 p value (adjusted) | 3.22E−09 | 0.030 | 0.013 | 0.031 | |
iPSC cardiomycoytes treated with lapatinib | |||||
 Genes uploaded to enrichment analysis | 1077/1358 | 1077/1358 | 1077/1358 | 1077/1358 | 1077/1358 |
 Uploaded genes in category | 173 | 21 | 21 | 12 | 12 |
 Expected genes in category | 115.54 | 5.64 | 6.31 | 1.97 | 2.22 |
 Category fold enrichment | 1.5 | 3.72 | 3.33 | >5 | >5 |
 p value (adjusted) | 4.94E−04 | 0.004 | 0.022 | 0.009 | 0.030 |
ERBB2-overexpressing cancer cell lines treated with trastuzumab | |||||
 Genes uploaded to enrichment analysis | 2097/2272 | 2097/2272 | 2097/2272 | 2097/2272 | 2097/2272 |
 Uploaded genes in category | 340 | 32 | 32 | 22 | 22 |
 Expected genes in category | 224.97 | 10.98 | 12.29 | 3.83 | 4.33 |
 Category fold enrichment | 1.51 | 2.91 | 2.6 | >5 | >5 |
 p value (adjusted) | 1.23E−10 | 0.001 | 0.014 | 1.12E−06 | 1.06E−05 |